We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (Hi DAC) based induction chemotherapy.
- Authors
Ling, Victoria; Burnett, Alan K.; Bradstock, Ken; Seymour, John F.; Hills, Robert K.; Wei, Andrew
- Abstract
This article discusses a study which examined the clinical utility of the Great Britain Medical Research Council (MRC) risk score in patients with de novo acute myeloid leukemia (AML) achieving complete remission after induction chemotherapy. Investigators delivered high-dose cytarabine (HiDAC)-based induction chemotherapy as the initial treatment to AML patients. They learned the value of the MRC clinical score in identifying AML patients.
- Subjects
UNITED Kingdom; ACUTE myeloid leukemia; DISEASE remission; DISEASE risk factors; CYTARABINE; MEDICAL Research Council (Great Britain)
- Publication
British Journal of Haematology, 2013, Vol 160, Issue 6, p861
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12178